# Efficacy of Macrolide Immunomodulation in Severe Sepsis.

> **NCT00708799** · PHASE2 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 100 (estimated)

## Conditions studied

- Systemic Inflammatory Response Syndrome

## Interventions

- **OTHER:** Azithromycin on admission - not enrolled in the RCT

## Key facts

- **NCT ID:** NCT00708799
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Safety evaluation due to recent publications.
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708799, "Efficacy of Macrolide Immunomodulation in Severe Sepsis.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00708799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*